Adjuvant Chemotherapy Including Cisplatin in Endometrial Carcinoma
| Autor: | Hidehiko Fujimura, Fumitaka Kikkawa, Hidenori Oguchi, Nobuo Nakashima, Shigehiko Mizutani |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Pirarubicin Urology Disease-Free Survival chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Cyclophosphamide Survival rate Survival analysis Etoposide Aged Gynecology Chemotherapy business.industry Endometrial cancer Obstetrics and Gynecology Middle Aged medicine.disease Nitrogen mustard Endometrial Neoplasms Survival Rate Treatment Outcome Reproductive Medicine chemistry Chemotherapy Adjuvant Doxorubicin CA-125 Antigen Lymphatic Metastasis Multivariate Analysis Female Cisplatin business medicine.drug |
| Zdroj: | Gynecologic and Obstetric Investigation. 50:127-132 |
| ISSN: | 1423-002X 0378-7346 |
| DOI: | 10.1159/000010297 |
| Popis: | To determine the outcome of patients with endometrial endometrioid adenocarcinoma following adjuvant chemotherapy, CAP (cyclophosphamide, pirarubicin and cisplatin) and EP (etoposide and cisplatin) were assigned at random to patients with Ic or more advanced stage carcinoma, and their efficacy was compared. These patients were treated by the Tokai Endometrial Cancer Study Group (Nagoya University and related institutions) between January 1992 and June 1996. The 5-year survival rate was 88.4% in the CAP group and 95.1% in the EP group; the difference between the two groups was not significant (p = 0.3496). The disease-free survival rate was 80.3% in the CAP group and 84.8% in the EP group (nonsignificant: p = 0.4533). However, the 5-year disease-free survival rates were 95.1 and 71.0% in patients with preoperative CA125 levels |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|